Work

POSTER: IBCL-1121 GOLSEEK-4: A Multicenter Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Golcadomide + Rituximab Vs Investigator’s Choice in Patients With Relapsed/Refractory Follicular Lymphoma

Year: 2025

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(25)01137-1

Authors: Alex Herrera, Eliza Hawkes, Clémentine Sarkozy, Yuqin Song, Muhit Özcan, Franck Morschhauser, Parth Rao, Alev Akyol, Antonia Di Micco, Adrien Petel, Akshay Sudhindra, Serena Perna, Charalambos (Babis) Andreadis

Institutions: City Of Hope National Medical Center, Austin Health, Olivia Newton-John Cancer Research Institute, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, Peking University Cancer Hospital, Ankara University, Université de Lille, Centre Hospitalier Universitaire de Lille, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), University of California, San Francisco

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413776176

FWCI:

Cites:

Cited by:

Related to: 10